GlassScriptPhysician profile
Joseph A Volpe
NPI 1114983566
$1,063.11
in general payments reported to CMS, 2019-2025
27 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.46 · 2020: $86.07 · 2021: $293 · 2022: $64.88 · 2023: $67.00 · 2024: $327 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546 · Consulting Fee: $31.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.29 |
| Consulting Fee | $31.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $162.37 | 2019-2022 | |
| Ucb, INC. | $113.45 | 2024-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Acadia Pharmaceuticals INC | $82.56 | 2024-2025 | Nuplazid |
| Emd Serono, INC. | $81.72 | 2021-2024 | |
| Biogen, INC. | $78.70 | 2021-2022 | |
| Bioventus LLC | $69.38 | 2023-2024 | Durolane, Durolane |
| Abbott Laboratories | $44.63 | 2023-2024 | Proclaim |
| Arbor Pharmaceuticals, INC. | $32.75 | 2020-2021 | |
| Adma Biomanufacturing LLC | $31.61 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.13 | 2021 | |
| Horizon Therapeutics Plc | $24.60 | 2020 | |
| Upsher-Smith Laboratories LLC | $24.54 | 2020 | |
| Abbvie INC. | $24.18 | 2025 | |
| Genentech USA, INC. | $23.87 | 2024 | Ocrevus |
| Depuy Synthes Sales INC. | $23.22 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $22.91 | 2024 | Haegarda |
| Allergan, INC. | $22.32 | 2021 | |
| Nevro Corp. | $22.25 | 2024 | Senza |
| Tg Therapeutics, INC. | $21.28 | 2025 | |
| Eisai INC. | $20.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.46 | 2021 | |
| Mdd US Operations, LLC | $18.03 | 2024 | Gocovri |
| Alnylam Pharmaceuticals INC. | $17.79 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $15.30 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.02 | 2024 | Eohilia |
| Amneal Pharmaceuticals LLC | $13.80 | 2025 | Crexont |
| Idorsia Pharmaceuticals US INC | $13.55 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Volpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.